*ST Xiangxue: Announcement on the appointment and adjustment of senior management personnel
Securities code: 300147 Securities abbreviation: *ST Xiangxue Announcement number: 2026-033
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Announcement on Appointment and Adjustment of Senior Management Personnel
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Guangzhou Xiangxue Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 36th meeting of the ninth board of directors on June 5, 2026, and reviewed and approved the "Proposal on the Appointment and Adjustment of Senior Management Personnel", agreeing to appoint the following personnel as the company's senior management personnel, with a term starting from the date of review and approval by the Board of Directors to the expiration date of the ninth Board of Directors. At the same time, adjustments will be made to the senior management personnel.
1. Appointment of senior management personnel
In accordance with the relevant provisions of the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the Articles of Association, the company's board of directors reviewed the proposed senior managers after being nominated by the company's general manager Mr. Wang Yonghui and reviewed by the nomination committee of the board of directors. The situation is as follows:
The company's board of directors has reviewed the academic qualifications, work experience, employment status and other relevant information of Mr. Zhao Qibin (see the attachment for resume) and Mr. Zheng Zhong (see the attachment for resume) and believes that they have the professional knowledge and decision-making, coordination and execution capabilities to serve as senior managers of the company. It was agreed to appoint Mr. Zhao Qibin as the company's general manager of marketing, with a term commencing from the date of review and approval by the board of directors until the expiration of the term of the ninth session of the board of directors; it was agreed to appoint Mr. Zheng Zhong as the company's financial officer, with a term of office from the date of review and approval by the board of directors to the expiration date of the term of the ninth session of the board of directors.
2. Adjustment of senior management personnel
In combination with the company's strategic development plan and actual operational development needs, the board of directors decided to adjust the company's original senior management personnel and positions. Mr. Tan Guanghua's position will be adjusted to the position of assistant to the president. Mr. Lu Feng will no longer serve as the company's acting financial director and hold other positions in the company.
Announcement is hereby made.
Board of Directors of Guangzhou Xiangxue Pharmaceutical Co., Ltd.
June 8, 2026
Attachments:
Zhao Qibin, male, born in 1987, Chinese nationality, no permanent residence abroad, bachelor’s degree. He once served as the company's marketing regional manager, North District KA director, Northeast region director, formula granule director, Chinese medicine piece director, medical director, e-commerce director, and marketing deputy general manager; he is currently the company's marketing general manager, legal representative and chairman of subsidiary Guangzhou Xiangxue Smart Traditional Chinese Medicine Co., Ltd., legal representative of Xiangxue Smart Traditional Chinese Medicine Clinic, and director of subsidiary Bozhou Huqiao Pharmaceutical Co., Ltd.
As of the date of this announcement, Mr. Zhao Qibin holds 12,000 shares of the company and has no related relationships with shareholders, company directors and senior managers who hold more than 5% of the company's voting shares. It has not been punished by the China Securities Regulatory Commission and other relevant departments or stock exchanges, and has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations. The circumstances stipulated in the Self-Regulatory Supervision Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 2 - Standardized Operation of GEM Listed Companies and the Articles of Association of the Company have not been disclosed by the China Securities Regulatory Commission on the illegal and untrustworthy information public inquiry platform in the securities and futures markets, and they are not deemed to be persons subject to enforcement for breach of trust. His qualifications are in compliance with relevant laws and regulations such as the Company Law, the Stock Listing Rules of the Shenzhen Stock Exchange’s Growth Enterprise Market, the Shenzhen Stock Exchange’s Self-Regulatory Guidelines for Listed Companies No. 2—Standardized Operations of Companies Listed on the Growth Enterprise Market, and the Articles of Association of the Company.
Zheng Zheng, male, born in 1985, Chinese nationality, no permanent residence abroad, bachelor's degree, holds ICPA, intermediate accountant certificate. He once served as the financial director of Dashenlin, the financial director of Ciming Medical Examination in Guangzhou, and the company's senior financial manager; he is currently the financial director of the company.
As of the date of this announcement, Mr. Zheng Zhong does not hold any shares in the company and has no relationship with shareholders, directors and senior managers holding more than 5% of the company’s voting shares. It has not been punished by the China Securities Regulatory Commission and other relevant departments or stock exchanges, and has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations. The circumstances stipulated in the Self-Regulatory Supervision Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 2 - Standardized Operation of GEM Listed Companies and the Articles of Association of the Company have not been disclosed by the China Securities Regulatory Commission on the illegal and untrustworthy information public inquiry platform in the securities and futures markets, and they are not deemed to be persons subject to enforcement for breach of trust. His qualifications are in compliance with relevant laws and regulations such as the Company Law, the Stock Listing Rules of the Shenzhen Stock Exchange’s Growth Enterprise Market, the Shenzhen Stock Exchange’s Self-Regulatory Guidelines for Listed Companies No. 2—Standardized Operations of Companies Listed on the Growth Enterprise Market, and the Articles of Association of the Company.